Nongastric marginal zone @entity1892 (NG-MZL) is a relatively uncommon @entity706 . From 1990 to 2005, a total of 247 @entity1 with histologically confirmed NG-MZL were analyzed. Ann Arbor stage I/II disease was present in 78% (167 out of 215). One hundred eighty-six @entity1 out of two hundred eight were categorized into the low/low-intermediate risk group (89%) according to International Prognostic Index (IPI). Eighty percent (172/215) were in low risk group according to @entity706 International Prognostic Index (FLIPI). Complete and partial remissions (CR and PR) were achieved in 140 (92.7%) and 8 (5.3%) of the 151 stage I/II @entity1 . Especially, radiation containing treatment achieved 96% CR rate (108 out of 113). In 38 @entity1 with stage III/IV, CR and PR were achieved in 17 (44.7%) and 11 (26.3%), respectively. The estimated five-year overall survival (OS) and progression-free survival (PFS) were 93.8% and 70.1%, respectively. Although @entity4349 -containing regimen could achieve higher CR rate, it did not improve PFS. Stage III/IV, low hemoglobin, poor performance status, high/high-intermediate IPI, poor risk FLIPI, and nodal MZL were poor prognostic factors for PFS. NG-MZL is an indolent disease. FLIPI has strong power to predict the prognosis of NG-MZL.

Nongastric marginal zone XXXX : analysis of 247 cases.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1892 :: ('MESH:D016393', 'Disease') :: ['B-cell lymphoma'] @entity706 :: ('MESH:D008223', 'Disease') :: ['indolent lymphoma', 'Follicular Lymphoma'] @entity4349 :: ('CHEBI:48120', 'Chemical') :: ['anthracycline']
@entity1892 :: (MESH:D016393,Disease) :: ['B-cell lymphoma']
